Artificial Intelligence (AI) is a broad term that encompasses many different things and is a kind of intelligence that is created by a machine instead of a human. AI is a technology that has been around for decades. It has been used in many different industries, but it is only recently that AI has been applied to the pharmaceutical industry.
The use of AI in regulatory affairs can be traced back to the early 2000s when the FDA started using computer-based systems to help them review and approve new drugs. The FDA’s computer-based systems are now able to process data more quickly than humans can, which means they are able to review more data than ever before.
"Click this LINK to check out my FlipBook and share your views"
Drug regulatory affairs is a complex field that requires knowledge in many different disciplines. AI can help simplify this process by automating tasks that are repetitive and error-prone, freeing up time for human experts to focus on more complex work. AI can also help identify regulatory risks and opportunities, allowing a company to plan its development strategy accordingly.
AI is slowly revolutionizing the drug regulatory affairs industry and FDA is also integrating with AI technologies for faster and more accurate reviews of new drugs.
The use of AI in regulatory affairs has many benefits for the pharmaceutical industry. It can be used for quicker and more accurate reviews of new drugs, it can identify adverse events at an early stage and provide early warning signals, it can help with data mining, and it can increase efficiency in general.
AI in Labeling
The health agencies will be using more AI-based technologies in labeling and other areas of regulatory affairs. For instance, in drug labeling, AI will be using machine learning algorithms that can read and understand the text on a label, identify any potential errors, and make suggestions for corrections.
In addition to having a better understanding of what a drug is, AI can help companies understand how the public understands their claims. This will allow them to prepare better marketing materials.
AI in Regulatory Publishing
The regulatory publishing industry will undergo a major transformation with the introduction of Artificial Intelligence in a few years.
Regulatory publishing is a process of publishing regulatory information about a drug in XML format, which includes the submission of data to regulatory authorities, such as the FDA, and other health agencies. The process is time-consuming and requires a lot of human effort. Hyperlinking and bookmarking will be automated by concepts of Machine Learning and will be more efficient than ever.
AI in Regulatory Submissions
AI will be used to automate the process of regulatory submissions, which will help pharmaceutical companies save time and money by avoiding capital-intensive investments in compliance and regulation. AI can help in this process by automating some tasks that are repetitive and time-consuming for humans to do. For example, AI can be used to automatically generate regulatory documents from templates or extract data from clinical trials.
By using AI to analyze large quantities of data, it’s possible to identify patterns and relationships that would be impossible for humans alone. This shows that AI is a key driver of innovation in drug development.
In regulatory affairs, AI will help to accelerate the review process of developing new medicines and bringing them faster to the market. The use of AI in drug regulatory affairs is still in its infancy, but it will likely grow as more and more companies adopt this technology.
HOLD ON! IF YOU HAVE READ THIS ARTICLE FULLY, I JUST WANT TO TELL YOU A SECRET…
Yes, a Secret! This article was not written by me, yes, I repeat this article was NOT written by me (Sharan Murugan). It was an Artificial Intelligence Writing Assistant Application that generated the whole content for me and I did just a few tweaks and have given my personal touch! That’s it!
Interesting right? This year for the first time in the world, AI-designed drugs from scratch have entered the Phase-I clinical trials. That’s how AI has evolved and will change the landscape of every segment in the pharma industry and regulatory affairs will be no exception.
The change is inevitable but the question is are you ready for it?
Comments